Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Abiomed Inc - Key Facts

Abiomed Inc - Key Employees

Abiomed Inc - Key Employee Biographies

Abiomed Inc - Major Products and Services

Abiomed Inc - History

Abiomed Inc - Company Statement

Abiomed Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Abiomed Inc - Business Description

Product Category: Impella Product Revenue

Performance

Product Category: Service and Other Revenue

Performance

Geographical Segment: International

Performance

Geographical Segment: The US

Performance

R&D Overview

Abiomed Inc - Corporate Strategy

Abiomed Inc - SWOT Analysis

SWOT Analysis - Overview

Abiomed Inc - Strengths

Abiomed Inc - Weaknesses

Abiomed Inc - Opportunities

Abiomed Inc - Threats

Abiomed Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Abiomed Inc, Medical Equipment, Deals By Year, 2013 to YTD 2019

Abiomed Inc, Medical Equipment, Deals By Type, 2013 to YTD 2019

Abiomed Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

May 02, 2019: Abiomed announced Q4 FY 2019 revenue of $207 million and 31.6% operating margin

Apr 23, 2019: Clinical data highlights advantages of protected PCI to enable complete revascularization and improved patient quality of life

Feb 20, 2019: $100 million invested in clinical research for Impella

Jan 31, 2019: Abiomed Announces Q3 FY 2019 Record Revenue of $201 Million, up 30% over Prior Year

Jan 07, 2019: Abiomed Announces Preliminary Q3 FY 2019 Revenue of $201 Million, Up 30% Over Prior Year and Increases Full Year Guidance

Nov 01, 2018: Abiomed announces Q2 FY 2019 record revenue of $182 Million, up 37% over prior year

Sep 24, 2018: Data presented at TCT 2018 shows use of Impella and best practices increases cardiogenic shock survival

Jul 26, 2018: Abiomed announces Q1 FY 2019 record revenue of $180 million, Up 36% over prior year

May 03, 2018: Abiomed Announces Q4 FY 2018 Revenue of $174 Million, Up 40%, and Total Year Revenue of $594 Million, Up 33%, Over Prior Year

Mar 30, 2018: Abiomed to Appoint New Chief Financial Officer Todd A. Trapp

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

Abiomed Inc (ABMD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Abiomed Inc (Abiomed) provides mechanical circulatory support devices and develops, manufactures and markets novel technologies that replace or assist the pumping function in a failing heart. The company’s heart support and recovery product portfolio includes catheters for circulatory support; minimally invasive implantable cardiac assist devices; and percutaneous catheter-based devices including micro heart pumps, expandable catheter pumps and axial flow pumps. Abiomed also offers automated controllers, designed to control and monitor the catheter performance and display real time hemodynamic and catheter position information. It has manufacturing facilities in Danvers, Massachusetts; and Aachen, Germany. The company sells its products through direct sales and distributors in the Americas, Europe, Asia and the Middle East. Abiomed is headquartered in Danvers, Massachusetts, the US.

Abiomed Inc Key Recent Developments

May 02,2019: Abiomed announced Q4 FY 2019 revenue of $207 million and 31.6% operating margin
Apr 23,2019: Clinical data highlights advantages of protected PCI to enable complete revascularization and improved patient quality of life
Feb 20,2019: $100 million invested in clinical research for Impella
Jan 31,2019: Abiomed Announces Q3 FY 2019 Record Revenue of $201 Million, up 30% over Prior Year
Jan 07,2019: Abiomed Announces Preliminary Q3 FY 2019 Revenue of $201 Million, Up 30% Over Prior Year and Increases Full Year Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company